NAMPT inhibition coincided with NAD+ depletion, the inhibition of NAD+ consuming enzymes, and suppressed cytokine release, indicating that targeting the NAD+ salvage pathway constitutes a promising target for IBD management [19]. The gene discussed is NAMPT; the disease is inflammatory bowel disease.